Authentic IgM Fc Receptor (FcμR).

[1]  D. Czajkowsky,et al.  Glycan-independent binding and internalization of human IgM to FCMR, its cognate cellular receptor , 2017, Scientific Reports.

[2]  M. Reth,et al.  The FcμR Limits Tonic BCR Signaling by Regulating IgM-BCR Expression , 2017, Nature Immunology.

[3]  Sudhir Gupta,et al.  FcμR in human B cell subsets in primary selective IgM deficiency, and regulation of FcμR and production of natural IgM antibodies by IGIV. , 2016, Human immunology.

[4]  C. Wendtner,et al.  Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells. , 2016, Blood.

[5]  N. Baumgarth.  B-1 Cell Heterogeneity and the Regulation of Natural and Antigen-Induced IgM Production , 2016, Front. Immunol..

[6]  J. Coligan,et al.  Emerging Functions of Natural IgM and Its Fc Receptor FCMR in Immune Homeostasis , 2016, Front. Immunol..

[7]  T. Jacobs,et al.  The application of anti-Toso antibody enhances CD8(+) T cell responses in experimental malaria vaccination and disease. , 2015, Vaccine.

[8]  Rona S. Gertner,et al.  Single-Cell Genomics Unveils Critical Regulators of Th17 Cell Pathogenicity , 2015, Cell.

[9]  S. Fillatreau.  Regulatory plasma cells. , 2015, Current opinion in pharmacology.

[10]  T. Vanden Berghe,et al.  Passenger Mutations Confound Interpretation of All Genetically Modified Congenic Mice. , 2015, Immunity.

[11]  Ruth L. Seal,et al.  Nomenclature of Toso, Fas Apoptosis Inhibitory Molecule 3, and IgM FcR , 2015, The Journal of Immunology.

[12]  T. Tsubata,et al.  FcμR Interacts and Cooperates with the B Cell Receptor To Promote B Cell Survival , 2015, The Journal of Immunology.

[13]  J. Kearney,et al.  Unique Ligand-Binding Property of the Human IgM Fc Receptor , 2015, The Journal of Immunology.

[14]  A. Masotti,et al.  Sialylation of N-Linked Glycans Influences the Immunomodulatory Effects of IgM on T Cells , 2015, The Journal of Immunology.

[15]  J. L. Ding,et al.  Natural Antibodies Bridge Innate and Adaptive Immunity , 2015, The Journal of Immunology.

[16]  A. Wiestner,et al.  Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. , 2014, Cancer research.

[17]  Yusuke Suzuki,et al.  Enhanced auto-antibody production and Mott cell formation in FcμR-deficient autoimmune mice. , 2014, International immunology.

[18]  K. Honjo,et al.  Monoclonal antibodies specific for human IgM Fc receptor inhibit ligand-binding activity. , 2014, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[19]  T. Mak,et al.  Toso regulates differentiation and activation of inflammatory dendritic cells during persistence-prone virus infection , 2014, Cell Death and Differentiation.

[20]  J. Ravetch,et al.  Type I and type II Fc receptors regulate innate and adaptive immunity , 2014, Nature Immunology.

[21]  L. Hellman,et al.  Fc Receptors for Immunoglobulins and Their Appearance during Vertebrate Evolution , 2014, PloS one.

[22]  T. Miyawaki,et al.  The Long Elusive IgM Fc Receptor, FcμR , 2014, Journal of Clinical Immunology.

[23]  T. Mak,et al.  Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells , 2014, Proceedings of the National Academy of Sciences.

[24]  K. Honjo,et al.  Is Toso/IgM Fc receptor (FcμR) expressed by innate immune cells? , 2013, Proceedings of the National Academy of Sciences.

[25]  T. Mak,et al.  Reply to Honjo et al.: Functional relevant expression of Toso on granulocytes , 2013, Proceedings of the National Academy of Sciences.

[26]  F. Nimmerjahn,et al.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system? , 2013, Nature Reviews Immunology.

[27]  J. Coligan,et al.  Mouse IgM Fc Receptor, FCMR, Promotes B Cell Development and Modulates Antigen-Driven Immune Responses , 2013, The Journal of Immunology.

[28]  G. Nolan,et al.  Involvement of Toso in activation of monocytes, macrophages, and granulocytes , 2013, Proceedings of the National Academy of Sciences.

[29]  F. Pattou,et al.  TOSO promotes β-cell proliferation and protects from apoptosis. , 2012, Molecular metabolism.

[30]  T. Kurosaki,et al.  Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival, and humoral immune responses , 2012, Proceedings of the National Academy of Sciences.

[31]  J. Kearney,et al.  Altered Ig levels and antibody responses in mice deficient for the Fc receptor for IgM (FcμR) , 2012, Proceedings of the National Academy of Sciences.

[32]  J. Coligan,et al.  Toso, a Functional IgM Receptor, Is Regulated by IL-2 in T and NK Cells , 2012, The Journal of Immunology.

[33]  K. Honjo,et al.  Is Toso an antiapoptotic protein or an Fc receptor for IgM? , 2012, Blood.

[34]  Randall S. Davis,et al.  Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia. , 2011, Blood.

[35]  A. Wiestner,et al.  TOSO, the Fcμ Receptor, Is Highly Expressed on Chronic Lymphocytic Leukemia B Cells, Internalizes upon IgM Binding, Shuttles to the Lysosome, and Is Downregulated in Response to TLR Activation , 2011, The Journal of Immunology.

[36]  S. Morrison,et al.  Characterization of IgA and IgM binding and internalization by surface-expressed human Fcα/μ receptor. , 2011, Molecular immunology.

[37]  J. Ravetch,et al.  Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies , 2011, Science.

[38]  T. Mak,et al.  Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitating RIP1 ubiquitination. , 2011, Blood.

[39]  J. Wienands,et al.  The signaling tool box for tyrosine-based costimulation of lymphocytes. , 2011, Current opinion in immunology.

[40]  Klimovich Vb.  IgM and its receptors: Structural and functional aspects , 2011 .

[41]  M. Caligiuri,et al.  Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.

[42]  M. Ehrenstein,et al.  The importance of natural IgM: scavenger, protector and regulator , 2010, Nature Reviews Immunology.

[43]  Hideaki Shima,et al.  Identification of TOSO/FAIM3 as an Fc receptor for IgM. , 2010, International immunology.

[44]  T. Kitamura,et al.  Identity of the elusive IgM Fc receptor (FcμR) in humans , 2009, The Journal of experimental medicine.

[45]  T. Tsubata,et al.  Recruitment of the cytoplasmic adaptor Grb2 to surface IgG and IgE provides antigen receptor–intrinsic costimulation to class-switched B cells , 2009, Nature Immunology.

[46]  M. Wabl,et al.  Immunosuppressive human anti‐lymphocyte autoantibodies specific for the type 1 sphingosine 1‐phosphate receptor , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  A. Ultsch,et al.  Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. , 2008, Blood.

[48]  E. Meffre,et al.  Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation , 2008, Molecular medicine.

[49]  M. Okusa,et al.  Naturally Occurring IgM Anti-Leukocyte Autoantibodies (IgM-ALA) Inhibit T Cell Activation and Chemotaxis1 , 2008, The Journal of Immunology.

[50]  A. Shibuya,et al.  Unusual biochemical features and follicular dendritic cell expression of human Fcα/μ receptor , 2007 .

[51]  Kelly J. Morris,et al.  SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. , 2007, Blood.

[52]  C. Kaetzel.  The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces , 2005, Immunological reviews.

[53]  T. Kinashi,et al.  Intracellular signalling controlling integrin activation in lymphocytes , 2005, Nature Reviews Immunology.

[54]  Kevin R. Coombes,et al.  Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies , 2004, Bioinform..

[55]  A. Cappione,et al.  Lupus IgG VH4.34 Antibodies Bind to a 220-kDa Glycoform of CD45/B220 on the Surface of Human B Lymphocytes1 , 2004, The Journal of Immunology.

[56]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[57]  R. Kimberly,et al.  FcγRs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody-Based Therapeutics1 , 2003, The Journal of Immunology.

[58]  A. Zuercher,et al.  B1 Cells Contribute to Serum IgM, But Not to Intestinal IgA, Production in Gnotobiotic Ig Allotype Chimeric Mice1 , 2003, The Journal of Immunology.

[59]  Yasunobu Miyake,et al.  Actin cytoskeleton is required for early apoptosis signaling induced by anti-Fas antibody but not Fas ligand in murine B lymphoma A20 cells. , 2002, Biochemical and biophysical research communications.

[60]  Ash A. Alizadeh,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[61]  L. Lanier,et al.  Immune inhibitory receptors. , 2000, Science.

[62]  C. Chen,et al.  Biochemical Nature and Cellular Distribution of the Paired Immunoglobulin-like Receptors, PIR-A and PIR-B , 1999, The Journal of experimental medicine.

[63]  S. Fazel,et al.  Structural and functional analysis of J chain-deficient IgM. , 1998, Journal of immunology.

[64]  G. Nolan,et al.  Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. , 1998, Immunity.

[65]  M. Cooper,et al.  The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[66]  F. Vély,et al.  Conservation of structural features reveals the existence of a large family of inhibitory cell surface receptors and noninhibitory/activatory counterparts. , 1997, Journal of immunology.

[67]  A. Coutinho,et al.  The repertoire of serum IgM in normal mice is largely independent of external antigenic contact , 1997, European journal of immunology.

[68]  A. Yamauchi,et al.  Target cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events. , 1996, Blood.

[69]  A. Verhoeven,et al.  Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR gamma chain. Molecular basis for CD89/FcR gamma chain association. , 1995, The Journal of biological chemistry.

[70]  S. Nagata,et al.  TCR/CD3 coupling to Fas-based cytotoxicity , 1995, The Journal of experimental medicine.

[71]  K. Schneweis,et al.  Anti‐lymphocyte antibodies in plasma of HIV‐1–infected patients preferentially react with MHC class Il‐negative T cells and are linked to antibodies against gp41 , 1994, Clinical and experimental immunology.

[72]  J. Ravetch.  Fc receptors: Rubor redux , 1994, Cell.

[73]  M. Cooper,et al.  Characterization of an IgM Fc-binding receptor on human T cells. , 1993, Journal of immunology.

[74]  A. Duchemin,et al.  Association of the high-affinity receptor for IgG (Fc gamma RI) with the gamma subunit of the IgE receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[75]  J. W. Brewer,et al.  Direct evidence that J chain regulates the polymeric structure of IgM in antibody-secreting B cells. , 1992, The Journal of biological chemistry.

[76]  D. Brautigan,et al.  Differentiation-induced changes in protein-tyrosine phosphatase activity and commensurate expression of CD45 in human leukemia cell lines. , 1992, Cancer research.

[77]  M. Reichlin,et al.  Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. , 1992, The Journal of clinical investigation.

[78]  M. Cooper,et al.  Biochemical nature of an Fc mu receptor on human B-lineage cells , 1990, The Journal of experimental medicine.

[79]  R. Williams,et al.  Isotype, distribution and target analysis of lymphocyte reactive antibodies in patients with human immunodeficiency virus infection. , 1989, Clinical immunology and immunopathology.

[80]  G. Opelz,et al.  Lymphocyte autoantibodies and alloantibodies in HIV-positive haemophilia patients. , 1989, Clinical and experimental immunology.

[81]  J. Kinet,et al.  Complete structure and expression in transfected cells of high affinity IgE receptor , 1989, Nature.

[82]  R. Donnelly,et al.  Specificity of anti-lymphocyte antibodies in sera from patients with AIDS-related complex (ARC) and healthy homosexuals. , 1988, Clinical and experimental immunology.

[83]  T. Suzuki,et al.  IgM binding protein expressed by activated B cells. , 1987, Journal of immunology.

[84]  A. Weiss,et al.  Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line , 1984, The Journal of experimental medicine.

[85]  S. Sasaki,et al.  Germfree mice reared on an "antigen-free" diet. , 1978, Laboratory animal science.

[86]  R. Winchester,et al.  Receptors for IgM on certain human B lymphocytes. , 1977, Journal of immunology.

[87]  W. Knapp,et al.  Receptors for IgM-coated erythrocytes on chronic lymphatic leukemia cells. , 1977, Journal of immunology.

[88]  T. Nasti,et al.  The old but new IgM Fc receptor (FcμR). , 2014, Current topics in microbiology and immunology.

[89]  P. Hogarth,et al.  Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcγRIIa , 2008 .

[90]  B. Heyman,et al.  Regulation of antibody responses via antibodies, complement, and Fc receptors. , 2000, Annual review of immunology.

[91]  J. Winfield,et al.  Anti-lymphocyte autoantibodies in systemic lupus erythematosus. , 1997, Transactions of the American Clinical and Climatological Association.

[92]  H Clevers,et al.  The T cell receptor/CD3 complex: a dynamic protein ensemble. , 1988, Annual review of immunology.

[93]  György Nagy,et al.  Cellular and Molecular Life Sciences REVIEW Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles , 2022 .